CALC logo

CALCIMEDICA INC

CALCNASDAQ
🏆 #4808 by market capEarnings Mar 2US Equity
$1.26▲ $0.09 (+7.69%)
Market closed · at close
🔔
Track CALC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.7%
7d▲ 4.1%
14d▼ 6.7%
30d▲ 2.4%
ytd▼ 96.2%
1y▼ 92.1%
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.20 – $1.33
52-Week Range
$1.00 – $36.00
Volume (shares)
91,265
Avg Volume (shares)
—
Shares Outstanding
6.8M
Next Earnings
2027-03-02

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.64
Dividend Yield
—
Dilution (1yr)
+17.6%
CALC logo

CALCIMEDICA INC

CALC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$23M▼ −4.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▲ +0.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.0M▲ +17.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$6M YoY
StockOtter · stockotter.space

About CALCIMEDICA INC

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

Zacks Investment Research·10d ago

What Makes CalciMedica Inc. (CALC) a New Buy Stock

CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire·12d ago

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027

GlobeNewsWire·19d ago

CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC)

Defense World·Oct 12

CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts

Shares of CalciMedica Inc. (NASDAQ: CALC - Get Free Report) have been assigned a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a

GlobeNewsWire·Sep 8

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC)

GlobeNewsWire·Aug 27

CalciMedica Announces One-for-Five Reverse Stock Split

LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) c